3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
3
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Nonsquamous Non-small Cell Lung Cancer
1
Non-Small Cell Lung Cancer Metastatic
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
44
Carboplatin
17
Pemetrexed
14
Paclitaxel
13
Cisplatin
13
lenvatinib
5
Etoposide
5
Docetaxel
5
epacadostat
4
Gemcitabine
4
Albumin-Bound Paclitaxel
4
durvalumab
3
Nivolumab
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
olaparib
2
Saline Solution
2
Immune Checkpoint Inhibitors
2
Dexamethasone
2
Acetaminophen
2
sacituzumab govitecan
1
ribociclib
1
patritumab deruxtecan
1
osimertinib
1
etoposide phosphate
1
efineptakin alfa
1
cemiplimab
1
camrelizumab
1
avelumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
patritumab deruxtecan
×
Thoracic
×
Clear all
NCT04165070
2026-05-18
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
450 enrolled